| Bioactivity | Teneligliptin hydrobromide hydrate is a potent chemotype prolylthiazolidine-based DPP-4 inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50s of approximately 1 nM[1]. |
| Name | Teneligliptin hydrobromide hydrate |
| CAS | 1572583-29-9 |
| Formula | C22H30N6OS |
| Molar Mass | 426.58 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Fukuda-Tsuru S, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202. |
Teneligliptin hydrobromide hydrate
CAS: 1572583-29-9 F: C22H30N6OS W: 426.58
Teneligliptin hydrobromide hydrate is a potent chemotype prolylthiazolidine-based DPP-4 inhibitor, which competitively i
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.